卡瑞利珠单抗联合安罗替尼治疗小细胞肺癌的效果及安全性

Efficacy and safety of Carrelizumab combined with Arotinib in the treatment of small cell lung cancer

目的观察卡瑞利珠单抗联合安罗替尼治疗小细胞肺癌(SCLC)的效果及安全性。方法选取2017年11月至2019年10月九江市第一人民医院收治的76例SCLC患者作为研究对象,按随机数字表法将其分为观察组和对照组,各38例。对照组采用安罗替尼治疗,观察组采用卡瑞利珠单抗联合安罗替尼治疗,每3周为1个疗程,连续治疗6个疗程。比较两组患者临床疗效、生活质量、无进展生存期(PFS)、总生存期(OS)及不良反应发生率。结果两组的治疗客观缓解率(ORR)、疾病控制率(DCR)比较,差异无统计学意义(P>0.05)。观察组治疗2、4、6个疗程后Karnofsky评分法(KPS)评分高于对照组,观察组OS及PFS长于对照组,差异有统计学意义(P<0.05)。两组的不良反应总发生率比较,差异无统计学意义(P>0.05)。结论SCLC患者采用卡瑞利珠单抗联合安罗替尼治疗肿瘤效果较好,有利于提高患者生活质量,延长患者生存期,毒副作用小。

Objective To observe the efficacy and safety of Carrelizumab combined with Arotinib in the treatment of small cell lung cancer(SCLC).Methods A total of 76 patients with SCLC who were admitted to Jiujiang First People′s Hospital from November 2017 to October 2019 were selected as research objects.They were divided into control group and observation group according to random number table method,with 38 cases in each group.The control group was treated with Arotinib,and the observation group was treated with Carrelizumab combined with Arotinib,with a course of treatment every 3 weeks and 6 consecutive courses of treatment.The clinical efficacy,quality of life,progression-free survival(PFS),overall survival(OS)and adverse reactions were compared between the two groups.Results There was no statistical significance in objective response rate(ORR)and disease control rate(DCR)between the two groups(P>0.05).After 2,4 and 6 courses of treatment,the Karnofsky score(KPS)of the observation group was higher than that of the control group,and the OS and PFS of the observation group were longer than those of the control group,the differences were statistically significant(P<0.05).There was no statistical significance between the two groups in the total incidence of adverse reactions(P>0.05).Conclusion Patients with SCLC treated with Carrelizumab combined with Arotinib have better effect,which is conducive to improving the quality of life,prolonging the survival time of patients and reducing toxic and side effects.